RAPP Earnings Date: Nov 5, 2026 (Estimated) — Rapport Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
Updated
When is RAPP's next earnings date?
Rapport Therapeutics, Inc. Common Stock (RAPP) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.20.
How did RAPP do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Rapport Therapeutics, Inc. Common Stock posted EPS of -$1.19 versus the -$0.96 estimate, a miss of 22.7%. Revenue was $0 against a $2.2M estimate. The stock's 1-day post-earnings move was +0.6%.
How much does RAPP stock move after earnings?
RAPP beat EPS estimates in 4 of its last 6 reported quarters. Over the last 6 reports the stock moved an average of 4.3% (up or down) in the day after earnings.
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.96 | -1.19 | -22.68% | $0 | ❌ Miss | +0.57% | +15.69% | +15.38% |
| 2026-05-07 | Q1 2026 | -0.68 | -0.42 | +38.24% | $20.0M | ✅ Beat | +7.74% | +2.75% | -2.59% |
| 2026-03-10 | Q4 2025 | -0.66 | -0.72 | -9.09% | $0 | ❌ Miss | -2.98% | -9.56% | +10.31% |
| 2025-11-06 | Q3 2025 | -0.75 | -0.71 | +5.33% | $0 | ✅ Beat | -3.10% | -3.82% | +12.72% |
| 2025-03-11 | Q4 2024 | -0.61 | -0.57 | +6.56% | $0 | ✅ Beat | +8.34% | +23.10% | +5.44% |
| 2024-11-07 | Q3 2024 | -0.57 | -0.50 | +12.28% | $0 | ✅ Beat | +2.87% | -16.44% | -21.76% |
Showing last 6 quarters.